A series of 2′,3′-dideoxy (D2) and 2′,3′-didehydro-2′,3′-dideoxy (D4) 5-fluorocytosine nucleosides modified with substituted benzoyl, heteroaromatic carbonyl, cycloalkylcarbonyl and alkanoyl at the N 4 -position were synthesized and evaluated for anti-human immunodeficiency virus type 1 (HIV-1) and anti-hepatitis B virus (HBV) activity in vitro. For most D2-nucleosides, N 4 -substitutions improved the anti-HIV-1 activity markedly without increasing the cytotoxicity. In the D4-nucleosides series, some of the substituents at the N 4 -position enhanced the anti-HIV-1 activity with a modest increase in the cytotoxicity. The most potent and selective N 4 -modified nucleoside for the D2-series was N 4 -p-iodobenzoyl-D2FC, which had a 46-fold increase in anti-HIV-1 potency in MT-2 cells compared to the parent nucleoside D-D2FC. In the D4series, N 4 -p-bromobenzoyl-D4FC was 12-fold more potent in MT-2 cells compared to the parent nucleoside D-D4FC. All eight N 4 -p-halobenzoylsubstituted D2-and D4-nucleosides evaluated against HBV in HepAD38 cells demonstrated equal or greater potency than the two parental compounds, D-D2FC and D-D4FC. The N 4 -modification especially in the D2-nucleoside series containing the N 4 -nicotinoyl, o-nitrobenzoyl and n-butyryl showed a significant reduction in mitochondrial toxicity relative to the parent nucleoside analogue. Although the 5′-triphosphate of the parent compound (D-D4FC-TP) was formed from the N 4acyl-D4FC analogues in different cells, the levels of the 5′-triphosphate nucleotide did not correlate with the cell-derived 90% effective antiviral concentrations (EC 90 ), suggesting that a direct interaction of the triphosphates of these N 4 -acyl nucleosides was involved in the antiviral activity.
Since the discovery of 3′-deoxy-3′-azidothymidine (AZT), many 2′,3′-dideoxy-and 2′,3′-didehydro-2′,3′-dideoxynucleosides (D2N and D4N, respectively) have been synthesized and evaluated for anti-human immunodeficiency virus type 1 (HIV-1) activity. In general, cytosine nucleosides have been especially potent as anti-HIV and anti-hepatitis B virus (HBV) agents. Modifications of D2-and D4cytosine nucleosides have resulted in compounds with improved pharmacological, toxicological and virological profiles. These modifications include changes on both the sugar and the base moieties. Sugar modifications involving the replacement of the 3′-carbon by an oxygen or a sulfur atom resulted in the dioxolane and oxathiolane nucleosides, respectively. An example of the latter is the oxathiolane cytosine nucleoside, lamivudine (3TC), which was approved as an anti-HIV and anti-HBV drug ( Jarvis & Faulds, 1999; Perry & Faulds, 1997) . Base modification mainly focused on the 5-position of the cytosine. Typically, the replacement of hydrogen by fluorine at this position resulted in more potent antiviral nucleosides. These include β-D-and β-L-2′,3′dideoxy-5-fluorocytine (D-D2FC and L-D2FC) (Gosselin et al., 1994; Kim et al., 1987; Lin et al., 1994) , (-)-cis-2hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane [(-)-FTC, emtricitabine] (Schinazi et al., 1992) , and β-Dand β-L-2′,3′-didehydro-2′,3′-dideoxy-5-fluorocytidine (D-D4FC and L-D4FC) (Lin et al., 1996; Schinazi et al., 2002; Shi et al., 1999) . (-)-FTC, developed by Gilead Sciences, is currently awaiting NDA approval for HIV, while D-D4FC, also known as DPC-817 or Reverset is in Phase II clinical trials for HIV by Pharmasset, Inc. L-D4FC (elvucitabine), in development by Achillion Pharmaceuticals, is in Phase I/II clinical trials for HIV and HBV.
Modifications of the 4-amino group of antiviral cytosine nucleosides have not been fully investigated. Only a few Introduction N 4 -substituted cytosine D2-and D4-nucleosides have been reported. In 1989, Kawaguchi et al. (1989) reported the synthesis and enzymatic hydrolysis of N 4 -benzoyl-2′,3′didehydro-2′,3′-dideoxycytidine. In 1993, the crystal structure of N 4 -benzoyl-2′,3′-dideoxycytidine was reported by Gulbis and MacKay (1993) . However, no antiviral activity was disclosed for these two compounds. In 1999, we reported the synthesis of N 4 -acetyl-and N 4 -isopropyl-D-D4FC (Shi et al., 1999) . However, the anti-HIV activity of these two analogues was modest compared to the parent compound D-D4FC. With respect to sugar-modified antiviral cytosine nucleosides, N 4 -acyl and -imine substituted 2′,3′-dideoxy-3′-C-hydroxymethylcytidine analogues have been synthesized and tested for their antiviral activity (Mauldin et al., 1998) . N 4 -Acetyl and N 4 -phosphonoacetyl 3TC nucleosides have also been previously synthesized (Charvet et al., 1994) . However, none of these N 4 -substituted cytosine nucleosides demonstrated improved antiviral activity over their parent compounds, 2′,3′-dideoxy-3′-Chydroxymethylcytidine and 3TC.
As a part of our continued search for antiviral nucleoside agents with improved therapeutic potential, modification of N 4 -substituents of 2′,3′-dideoxy-and 2′,3′-didehydro-2′,3′dideoxy-5-fluorocytidines was performed. Manipulation of the N 4 -substituent of the nucleosides is expected to change the chemical, biochemical and pharmacokinetic properties of the compounds, resulting in an increase in biochemical stability towards cytidine deaminases and potential improvement in intracellular transport, thus providing more potent antiviral candidates. This research yielded N 4 -acyl-substituted D-D2FC and D-D4FC derivatives with improved potency compared to their corresponding parent compounds. Herein, we report the synthesis, antiviral activity, cytotoxicity and in vitro mitochondrial toxicity of these N 4 -acyl-substituted-cytosine nucleosides.
Materials and methods

Chemistry
Anhydrous solvents were purchased from Aldrich Chemical Company, Inc. (Milwaukee, Wis., USA). 1 H NMR spectra were taken on a Varian Unity Plus 400 spectrometer at room temperature and reported in ppm downfield from internal tetramethylsilane. Deuterium exchange, decoupling experiments or 2D-COSY were performed in order to confirm proton assignments. Signal multiplicities are represented by s (singlet), d (doublet), dd (doublet of doublets), t (triplet), q (quadruplet), br (broad), bs (broad singlet) and m (multiplet). Mass spectra were recorded on a JEOL JMS-SX/SX102A/E mass spectrometer. Analytic TLC was performed on Whatman LK6F silica gel plates. Column chromatography was conducted on silica gel (Fisher, S733-1) at low pressure.
The N 4 -acyl-5-fluorocytosine D2-and D4-nucleosides were synthesized from the corresponding 5′-O-silyl protected D2FC and D4FC (2 and 3), by acylation with either a carboxylic acid chloride or an anhydride, followed by desilylation with TBAF, as shown in Figure 1 . 5′-O-TBDPSprotected D2FC (2) was prepared from 5′-O-TBDPS-2′phenylselenenyl-D2FC (1) by reduction with tributyltin hydride and triethylboron as previously described (Beach et al., 1992) , while 5′-O-TBDPS-protected D4FC (3) was prepared from 5′-O-TBDPS-2′-phenylselenenyl-D2FC (1) by oxidative elimination with 30% H 2 O 2 as reported earlier (Shi et al., 1999) . Compound 1 was prepared from the coupling reaction of 5-fluorocytosine and 2-phenylselenenyl-lactol acetate as previously described (Shi et al., 1999) . The two parent compounds D-D2FC and D-D4FC were prepared from their corresponding 5′-O-silyl protected precursors 2 and 3 by de-silylation with TBAF, as previously described (Beach et al., 1992; Shi et al., 1999) .
To a solution of 2 (131 mg, 0.28 mmol) and DMAP (5 mg) in anhydrous CH 2 Cl 2 (2 ml) and Et 3 N (0.5 ml) at 0°C was added 4-iodobenzoyl chloride (85 mg, 0.31 mmol). The reaction mixture was stirred at 0°C for 30 min, then at room temperature for another 3 h. After removal of the solvent by evaporation, the residue was dissolved in THF (3 ml), and TBAF (1 M solution in THF, 0.28 ml, 0.28 mmol) was added. After stirring for 2 h at room temperature, the solvent was evaporated, and the residue was purified by flash chromatography on silica gel eluting with CH 2 Cl 2 /MeOH (96:4) to give, after recrystallization from CH 2 Cl 2 /hexane, the title compound 7 as a yellow powder (48 mg, 37%). 1 H NMR (DMSO-d 6 ) δ 8.9 (bs, 1H, NH), 7.90-7.73 (m, 5H, H-6, arom.), 5.91 (bs, 1H, H-1′), 5.10 (m, 1H, OH), 4.14 (m, 1H, H-4′), 3.80, 3.57 (2m, 2H, H-5′), 2.35, 2.08 (2m, 2H, H-2′), 1.86 (m, 2H, H-3′); MS (FAB + ) m/z 458
To a solution of 3 (140 mg, 0.3 mmol) and DMAP (5 mg) in anhydrous CH 2 Cl 2 (2 ml) and Et 3 N (0.5 ml) at 0°C was added 4-fluorobenzoyl chloride (52 mg, 0.33 mmol). The reaction mixture was stirred at 0°C for 30 min, then at room temperature for another 2 h. After removal of the solvent by evaporation, the residue was dissolved in THF (3 ml), and TBAF (1 M solution in THF, 0.30 ml, 0.30 mmol) was added. After stirring for 2 h at room temperature, the solvent was evaporated and the residue was purified by flash chromatography on silica gel eluting with CH 2 Cl 2 /MeOH (96:4) to give, after recrystallization from CH 2 Cl 2 /hexane, the title compound 29 as a pale yellow solid (33 mg, 32%). 
Biology
Anti-HIV and cytotoxicity assay
Antiviral activity was assessed in three virological systems. First, anti-HIV-1 activity of the compounds was determined in human peripheral blood mononuclear (PBM) cells as previously described (Schinazi et al., 1992) . PBM cells (obtained from Atlanta Red Cross) were isolated by Ficoll-Hypaque discontinuous gradient centrifugation from healthy seronegative donors. Cells were stimulated with phytohaemagglutinin A (PHA) (Difco, Sparks, MD) for 2-3 days prior to use. HIV-1/LAI was used as the standard reference virus in the antiviral assays. Infections were done in bulk for 1 h with 200 TCID 50 /6×10 5 cells/well for a 24-well plate assay. Cells were added to a plate or flask containing a 10-fold serial dilution of the test compound. Assay medium was RPMI-1640 supplemented with heatinactivated 16% fetal bovine serum, 1.6 mM L-glutamine, 80 IU/ml penicillin, 80 µg/ml streptomycin, 0.0008% DEAE-Dextran, 0.045% sodium bicarbonate and 26 IU/ml recombinant interleukin-2 (Chiron Corp, Emeryville, Calif., USA). Zidovudine (AZT) was used as a positive control for the assay. Untreated and uninfected PBM cells were grown in parallel at equivalent cell concentrations as controls. The cells were maintained in a humidified 5% CO 2 -air at 37°C for 5 days and supernatants were collected for reverse transcriptase (RT) activity. Supernatants were centrifuged at 12000 rpm for 2 h to pellet the virus. The pellet was solubilized with vortexing in 100 µl virus solubilization buffer containing 0.5% Triton X-100, 0.8 M NaCl, 0.5 mM phenylmethylsulfonyl fluoride, 20% glycerol and 0.05 M Tris, pH 7.8. 10 µl of each sample were added to 75 µl RT reaction mixture [0.06 M Tris, pH 7.8, 0.012 M MgCl 2 , 0.006 M dithiothreitol, 0.006 mg/ml poly (rA) n oligo (dT) 12-18 , 96 µg/ml dATP and 62.2 Ci/mmol 3 Hthymidine triphosphate (Moravek Biochemicals, Brea, Calif., USA)] and incubated at 37°C for 2 h. The reaction was stopped by the addition of 100 µl 10% trichloroacetic acid containing 0.05% sodium pyrophosphate. The acid insoluble product was harvested onto filter paper using a Packard Harvester (Meriden, Conn., USA) and the radioactivity was read on a Packard Direct Beta Counter (Meriden, Conn., USA). The results were expressed in counts per min (CPM) per ml. The antiviral 50% effective concentration (EC 50 ) and 90% effective concentration (EC 90 ) were determined from the concentration-response curve using the median effect method (Belen'kii & Schinazi, 1994) .
In a second antiviral testing system, the potency of the compounds was determined by measurement of viral RNA accumulation in HIV-1RF-infected MT-2 cells (Bacheler et al., 1994) . The virus titre was established to determine the dilution producing 15-30 ng RNA per well of HIV RNA in 3 days of infection. HIV-1 RNA was quantified using biotinylated capture and alkaline phosphatasederivatized reporter oligonucleotides as described previous- ly (Bacheler et al., 1994) . In a third system, the effect of analogues on the replication of HIV-1 NL4-3 was determined using the InterCompany Consortium consensus p24 assay as previously described ( Jadhav et al., 1997) . Recombinant viruses were recovered by transfecting the appropriate NL4-3 plasmid by lipofection. Virus stocks recovered 7-10 days post-transfection were titred on MT-4 cells to determine if the dilution produced 1000-3000 ng p24 in 4 days. This dilution was then used in drug susceptibility assays, where drug was added 24 h post-infection of cells and p24 quantified by ELISA 3 days later.
Anti-HBV assay
The anti-HBV activity of the compounds was determined by treating the HepAD38 cell line carrying wild-type HBV under the control of tetracycline with compounds of interest at 100 µM (Ladner et al., 1997) . Removal of tetracycline from the medium [Tet (-)] results in the production of HBV in the supernatant. The levels of HBV in the culture supernatant fluids from cells treated with the compounds (at 100 µM) were compared with those of the untreated controls after 5 days. Control cultures with tetracycline [Tet (+)] were also maintained to determine the basal levels of HBV expression. 3TC was included as a positive control. Quantitation of the HBV DNA was performed by real-time PCR and using known HBV DNA standards (Stuyver et al., 2002) . Log reduction of HBV copy number was made in comparison to the control [Tet (-)] cultures with no drug treatment.
Cytotoxicity assay
The compounds were evaluated for their potential toxic effects on uninfected phytohaemagglutinin A-stimulated human PBM cells, in CEM (T-lymphoblastoid cell line obtained from American Type Culture Collection, Rockville, Md., USA) and Vero (African green monkey kidney) cells. Log phase Vero, CEM and PHA-stimulated human PBM cells were seeded at a density of 5×10 3 , 2.5×10 3 and 5×10 4 cells/well, respectively. All of the cells were plated in 96-well cell culture plates containing 10-fold serial dilutions of the test drug. The cultures were incubated for 3, 4 and 5 days for Vero, CEM and PBM, respectively, in a humidified 5% CO 2 -air at 37°C. At the end of incubation, MTT tetrazolium dye solution (Cell Titer 96‚ Aqueous One Solution Cell Proliferation Assay, Promega, Madison, Wis., USA) was added to each well and incubated overnight. The reaction was stopped with stop solubilization solution (Promega, Madison, Wis., USA). The plates were incubated for 5 h to ensure that the formazan crystals were dissolved. The plates were read at a wavelength of 570 nm using an ELISA plate reader (Bio-tek instruments, Inc., Winooski, Vt., USA, Model # EL 312e). The 50% inhibition concentration (IC 50 ) was determined from the concentration-response curve using the median effect method (Belen'kii & Schinazi, 1994) .
Q-PCR assay for mitochondrial DNA and rRNA gene in HepG2 cells
The compounds were assayed for their mitochondrial toxicity as previously described (Stuyver et al., 2002) . Briefly, lowpassage-number HepG2 cells were seeded at 5000 cells/well in collagen-coated 96-well plates. Test compounds were added to the medium to obtain final concentrations of 10 µM. On culture day 7, cellular nucleic acids were prepared by using commercially available columns (Rneasy 96 kit; Qiagen). The mitochondrial cytochrome oxidase subunit II (COXII) gene and rRNA gene were amplified in a multiplex Q-PCR protocol.
Assays for intracellular levels of D-D4FC-TP produced from various N 4 -acyl-D4FC in PBMC, MT-2 and MT-4 cells
The concentration of D-D4FC-TP was determined by LC-MS-MS in three different cell systems as described elsewhere (Shi et al., 2002) . Briefly, lysates of cells were extracted by protein precipitation and the filtered extracts were analysed by weak anion exchange liquid chromatography (WAX-LC) coupled to MS detection. By using a PE Sciex API 4000 triple quadrupole instrument operating in positive ion multiple reaction monitoring (MRM) mode, the method was able to achieve a lower limit of quantitation (LLOQ) of 5 fmol/10 6 cells in samples containing 3×10 6 lysed cells.
Results
According to Figure 1 , and by following the general procedures described above, 25 N 4 -acyl-substituted 2′,3′dideoxy-5-fluorocytidine and 26 N 4 -acyl-substituted 2′,3′didehydro-2′,3′-dideoxy-5-fluorocytidine compounds were synthesized and characterized by 1 H NMR and mass spectroscopy. These N 4 -acyl-substituted 2′,3′-dideoxy-5-fluorocytidine and 2′,3′-didehydro-2′,3′-dideoxy-5-fluorocytidine analogues were evaluated for antiviral activity and cytotoxicity, and compared to their parent compounds, D-D2FC and D-D4FC, respectively. The anti-HIV-1 activity and cytotoxicity of these N 4 -acyl-D2FC analogues are shown in Table 1 . Interestingly, most of the N 4 -acyl-modified D2FC analogues showed increased antiviral potency over the parent compound, D-D2FC. Only p-methoxylbenzoyl (11) and o-toluoyl (18) substituted nucleosides were less potent than D-D2FC. The most potent compound in MT-2 cells was N 4 -p-iodobenzoyl-D2FC (7), which had a 46-fold increase in anti-HIV-1 potency compared to D-D2FC. None of the N 4 -modified nucleosides showed significant toxicity in MT-2 cells, except for N 4 -n-butyryl-D2FC (27), which had an IC 50 of 7.2 µM. However, in PBM, CEM, Vero and HepG-2 cells, p-toluoyl (11), p-butylbenzoyl (21), n-butyryl (27) and cyclohexanecarbonyl (28) substituted nucleosides exhibited greater toxicity compared to the parent nucleoside. The heteroaromatic carbonyl substituted nucleosides (23-26) also showed a moderate increase in cytotoxicity compared to D-D2FC. The anti-HIV-1 activity and cytotoxicity of N 4 -acyl-D4FC analogues are shown in Table 2 . In comparison to D-D4FC, many of these N 4 -modified nucleosides showed an increased antiviral activity, while their cytotoxicities also increased in the tested cells. These include most m-and psubstituted benzoyl (29-32, 40, 42, 43 and 47) , heteroaromatic carbonyl (50), cyclopentanecarbonyl (51), cyclohexanecarbonyl (52) and heptanoyl (53) substituted D4FC analogues. In contrast, N 4 -p-methoxybenzoyl-D4FC (36) demonstrated a modestly improved antiviral activity without cytotoxicity in PBM and MT-2 cells in comparison to D-D4FC. Interestingly, whereas all the meta-and parasubstituted benzoyl modified D4-nucleosides demonstrated anti-HIV activity, the ortho-substituted D4-nucleosides (38, 41 and 44) were devoid of antiviral activity in MT-2 cells and were also markedly less potent in acute infected human PBM cells ( Table 2) .
The mitochondrial toxicity of the compounds were assayed using a Q-PCR protocol (Stuyver et al., 2002) on mitochondrial cytochrome c oxidase subunit II (COXII) gene and rRNA gene, and the results are presented in Tables 3 and 4. In the D2-nucleosides series, compared to the parent compound D2FC, only o-nitrobenzoyl (14), nicotinoyl (25) and n-butyryl (27) substituted nucleosides resulted in a significant decrease in mitochondrial (MitCoxII) and cellular (rRNA gene) toxicity; all other D2-nucleoside analogues showed a similar or moderate increase in mitochondrial toxicity. However, all these modified D2-nucleosides demonstrated markedly less mitochondrial toxicity than DDC. In the D4-nucleosides -, m-, p-methylbenzoyl (42-44) substituted D4FC analogues. Some selected N 4 -p-halobenzoyl substituted D2FC and D4FC analogues were evaluated against HBV in HepAD38 cells and the data are presented in Table 5 . Although the anti-HBV activity of these compounds are all in a moderate range, the data show clearly that all these halobenzoyl-modified nucleosides demonstrated an equal or better anti-HBV activity than their parent compounds, D-D2FC and D-D4FC. In general, these modifications resulted in an improved biological activity in the D-D2FC series compared to the D-D4FC analogues.
In order to understand if these compounds were acting merely as prodrugs for the parent compound, the intracellular levels of the parent nucleoside triphosphate, D-D4FC-TP, were measured in PBM, MT-2 and MT-4 cells exposed to selected N 4 -acyl-D4FC analogues ( Figure  2) . The levels of D-D4FC-TP detected in these cells did not correlate with the EC 90 values in any of the cell-based test systems.
Discussion
D-2′,3′-Dideoxy-and 2′,3′-didehydro-2′,3′-dideoxy-5-fluorocytidine derivatives with four types of N 4 -acyl modifications showed surprising changes in anti-HIV activity and cytotoxicity when compared to their parent compounds. The D2-and D4-nucleosides with alkanoyl or cycloalkanoyl substituents at N 4 -position normally retained antiviral activity, however, the cytotoxicity in various cells also increased remarkably in comparison to the parent compounds, D-D2FC and D-D4FC.
The D2-and D4-nucleosides modified with heteroaromatic carbonyl substituents, in general, showed improved antiviral activity, but the cytotoxicities were also increased. The only exception was N 4 -nicotinoyl-D4FC (49), which was devoid of antiviral activity. Hence, the N 4 -heteroaromatic carbonyl substituents may be useful for improving the nucleoside antiviral activity. N 4 -Benzoyl modifications are, in general, good substituents for improving the antiviral activity for D2-and D4-nucleosides. The positions of the substituents on the benzoyl moiety were found to be important. In general, mand p-substituted benzoyl modified D2-and D4-nucleosides resulted in improved antiviral activity, while the osubstituted benzoyl-D2FC and -D4FC resulted in little or no activity. The substituents on the benzoyl (halogen, nitro or alkyl groups) produced different effects on D2-versus D4-nucleosides. In the D2-nucleoside series, these benzoyl modifications greatly increased the antiviral activity without elevating the cytotoxicity, while in the D4-nucleoside series, the improvement in antiviral activity was not as remarkable, but more importantly, the cytotoxicity of these nucleosides was also increased. However, some D4-nucleosides with an N 4 -substituted benzoyl group showed improved antiviral activity with only a modest increase in cytotoxicity. For example, N 4 -p-bromobenzoyl-D4FC (31) and N 4 -p-iodobenzoyl-D4FC (32) showed a four-to eightfold increase in antiviral activity in MT-2 cells, with no change in cytotoxicity in MT-2 cells and only a moderate increase in toxicity in CEM cells compared to For the D-D2FC series, the most potent compound was 2′,3′-dideoxy-5-fluoro-N 4 -(p-iodobenzoyl)cytidine (7), which produced a 46-fold increase in anti-HIV potency in MT-2 cells and a 16-fold increase in PBM cells compared to the parent compound, D-D2FC. In the D-D4FC series, N 4 -p-bromobenzoyl-D4FC (31) exhibited greater than a 12-fold increase in anti-HIV-1 potency in MT-2 cells compared to the parent compound, D-D4FC. Interestingly, in agreement with the HIV-1 data, the anti-HBV activity of eight N 4 -benzoyl substituted D2-and D4-nucleoside analogues demonstrated equal or better activity than the corresponding two parent compounds.
The mitochondrial toxicity studies of these D2-and D4-nucleosides revealed that, in general, the D4-compounds are less toxic to mitochondrial than D2-derivatives. The N 4 -modifications of the D2-and D4-nucleosides indicated that some of the modifications significantly reduce the mitochondrial toxicity of the parent compound. This is especially apparent for the D2-nucleosides, which usually show severe mitochondrial toxicity in cells. Our results show that N 4 -modification of D2FC with nicotinoyl (25), o-nitrobenzoyl (14) and n-butyryl (27) substituents minimized the effect on the both mitochondrial DNA (MitCoxII) and cellular DNA (rRNA gene) levels. It is clear from the analysis of the D-D4FC-TP levels, that the N 4 -acyl-substituted D4-nucleosides do not act solely as prodrugs for the parent compound. The detection of the 5′-triphosphate of the parent compound, D-D4FC-TP, by mass spectroscopy from cells cultured in the presence of N 4 -acyl-D4FC analogues (Figure 2 ), indicate that these nucleosides can be cleaved intracellularly to produce the parent compound, D-D4FC. However, the D-D4FC-TP levels produced from these nucleoside analogues did not correlate with the antiviral activity EC 90 values in any of the cells tested ( Table 2 ). The data suggest that these modified nucleosides may function directly as antiviral agents, in addition to the prodrug mode. Further work is needed to establish the active metabolite for these modified nucleosides.
In summary, we have synthesized a series of N 4 -acylsubstituted D-D2FC and D-D4FC nucleosides and demonstrated that some analogues have an enhanced antiviral activity in comparison to their parent compounds. The modification of the N 4 -position with certain acyl substituents could be a general simple way to enhance the antiviral potency of cytosine nucleosides without necessarily increasing their cytotoxicity. 
